{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011145","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.406420+00:00","generated_at":"2026-06-17T05:08:47.776524+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted","bullets":["Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.","Funds to accelerate clinical trial of Biostage Esophageal Implant (BEI) for esophageal cancer/injury.","All Series E Preferred Stock plus accrued dividends will convert to ~675,000 common shares at $6.00, eliminating Series E.","FDA approved 10-patient Phase 1/2 trial for BEI; potential expansion to pediatric and bronchial indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011145","json":"https://secwatch.observer/filing/0001493152-23-011145.json","markdown":"https://secwatch.observer/filing/0001493152-23-011145.md","text":"https://secwatch.observer/filing/0001493152-23-011145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/0001493152-23-011145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:08:47.776524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16056583dc669339507a81cffd7622d05031b66f","claim":"Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors valued at $6 million (effective 2023-03-31).","evidence_excerpt":"On March 31, 2023, Biostage, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 1,000,967 shares of common stock for the aggregate purchase price of $6 million and a purchase price per unit of $6.00 (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/0001493152-23-011145-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$6 million"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}